Shijiazhuang Yiling Pharmaceutical (002603.SZ) subsidiary receives European CEP certificate for anastrozole API.

Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that recently, its wholly-owned subsidiary's subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (referred to as "Hengshui Wanyang"), received the Certificate of Suitability of the European Pharmacopoeia (referred to as "CEP certificate") for anastrozole API issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). It is reported that anastrozole is a drug widely used in the treatment of estrogen-related tumors. The acquisition of the CEP certificate for anastrozole by Hengshui Wanyang this time indicates the recognition and affirmation of the quality of this API by the regulated European market, marking that the product has the qualification to enter the EU and other markets that recognize the CEP certificate in the form of API, bringing a positive impact on the company's further expansion into the international market.